Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Get Free Report) TSE: AUP has been assigned a consensus rating of "Moderate Buy" from the six research firms that are presently covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $17.33.
Several equities analysts have recently issued reports on AUPH shares. Zacks Research cut Aurinia Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, July 21st. Bloom Burton upgraded Aurinia Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 20th. TD Cowen raised their target price on Aurinia Pharmaceuticals from $17.00 to $18.00 and gave the stock a "buy" rating in a report on Wednesday, October 21st. Wall Street Zen cut Aurinia Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, November 7th. Finally, Weiss Ratings cut Aurinia Pharmaceuticals from a "buy (b)" rating to a "buy (b-)" rating in a research report on Wednesday, November 4th.
Get Our Latest Analysis on Aurinia Pharmaceuticals
Institutional Investors Weigh In On Aurinia Pharmaceuticals
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. purchased a new position in shares of Aurinia Pharmaceuticals during the 2nd quarter valued at approximately $139,037,000. Goldman Sachs Group Inc. boosted its holdings in Aurinia Pharmaceuticals by 12.8% during the third quarter. Goldman Sachs Group Inc. now owns 6,338,866 shares of the biotechnology company's stock worth $102,658,000 after buying an additional 719,465 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Aurinia Pharmaceuticals by 4.6% during the first quarter. Renaissance Technologies LLC now owns 1,663,835 shares of the biotechnology company's stock worth $24,658,000 after buying an additional 73,700 shares in the last quarter. Allianz Asset Management GmbH acquired a new stake in Aurinia Pharmaceuticals during the second quarter valued at $14,284,000. Finally, Janus Henderson Group PLC grew its position in Aurinia Pharmaceuticals by 9.7% during the first quarter. Janus Henderson Group PLC now owns 757,435 shares of the biotechnology company's stock valued at $11,225,000 after buying an additional 66,806 shares during the period. Institutional investors and hedge funds own 36.83% of the company's stock.
Aurinia Pharmaceuticals Stock Performance
Shares of NASDAQ AUPH opened at $15.48 on Tuesday. The company has a 50 day simple moving average of $16.47 and a two-hundred day simple moving average of $15.73. The stock has a market cap of $2.07 billion, a price-to-earnings ratio of 6.76 and a beta of 1.40. The company has a current ratio of 6.12, a quick ratio of 5.67 and a debt-to-equity ratio of 0.06. Aurinia Pharmaceuticals has a 12 month low of $13.52 and a 12 month high of $19.25.
Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last released its quarterly earnings data on Friday, October 30th. The biotechnology company reported $0.23 earnings per share for the quarter, topping analysts' consensus estimates of $0.22 by $0.01. Aurinia Pharmaceuticals had a net margin of 97.68% and a return on equity of 22.99%. The firm had revenue of $83.70 million for the quarter, compared to analyst estimates of $83.61 million. As a group, analysts predict that Aurinia Pharmaceuticals will post 0.97 earnings per share for the current year.
Aurinia Pharmaceuticals Company Profile
(
Get Free Report)
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing treatments for autoimmune diseases. The Canadian company's work has centered on therapies for conditions that can affect the kidneys and other organs. Its lead product, Lupkynis (voclosporin), is an oral medicine approved in the United States to treat adults with active lupus nephritis, a kidney complication of systemic lupus erythematosus. It is used in combination with background immunosuppressive therapy. Aurinia, formerly known as Isotechnika, developed voclosporin as a treatment for lupus nephritis.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Aurinia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurinia Pharmaceuticals wasn't on the list.
While Aurinia Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.